US6465188B1
(en)
*
|
1990-06-11 |
2002-10-15 |
Gilead Sciences, Inc. |
Nucleic acid ligand complexes
|
DE69435100D1
(de)
|
1993-10-29 |
2008-06-26 |
Brigham & Womens Hospital |
Therapeutische verwendung von cis-element-fallen in vivo
|
US5670347A
(en)
|
1994-05-11 |
1997-09-23 |
Amba Biosciences Llc |
Peptide-mediated gene transfer
|
FR2730637B1
(fr)
|
1995-02-17 |
1997-03-28 |
Rhone Poulenc Rorer Sa |
Composition pharmaceutique contenant des acides nucleiques, et ses utilisations
|
US8071737B2
(en)
*
|
1995-05-04 |
2011-12-06 |
Glead Sciences, Inc. |
Nucleic acid ligand complexes
|
US6699843B2
(en)
*
|
1995-06-07 |
2004-03-02 |
Gilead Sciences, Inc. |
Method for treatment of tumors using nucleic acid ligands to PDGF
|
US6007838A
(en)
†
|
1995-06-07 |
1999-12-28 |
The United States Of America As Represented By The Secretary Of The Army |
Process for making liposome preparation
|
US6229002B1
(en)
*
|
1995-06-07 |
2001-05-08 |
Nexstar Pharmaceuticlas, Inc. |
Platelet derived growth factor (PDGF) nucleic acid ligand complexes
|
US5994315A
(en)
*
|
1995-06-07 |
1999-11-30 |
East Carolina University |
Low adenosine agent, composition, kit and method for treatment of airway disease
|
FR2739292B1
(fr)
*
|
1995-09-28 |
1997-10-31 |
Rhone Poulenc Rorer Sa |
Composition pharmaceutique utile pour la transfection d'acides nucleiques et ses utilisations
|
US6344436B1
(en)
*
|
1996-01-08 |
2002-02-05 |
Baylor College Of Medicine |
Lipophilic peptides for macromolecule delivery
|
US6096336A
(en)
*
|
1996-01-30 |
2000-08-01 |
The Stehlin Foundation For Cancer Research |
Liposomal prodrugs comprising derivatives of camptothecin and methods of treating cancer using these prodrugs
|
US6077834A
(en)
*
|
1996-02-09 |
2000-06-20 |
Cheng; Pi-Wan |
Receptor ligand-facilitated delivery of biologically active molecules
|
EP0906123A4
(de)
*
|
1996-03-15 |
1999-05-26 |
Univ Florida |
ANGIOTENSINOGEN-mRNA SPEZIFISCHE OLIGONUKLEOTIDE
|
AU710170B2
(en)
|
1996-05-08 |
1999-09-16 |
Nika Health Products Limited |
Cationic virosomes as transfer system for genetic material
|
US6080728A
(en)
*
|
1996-07-16 |
2000-06-27 |
Mixson; A. James |
Carrier: DNA complexes containing DNA encoding anti-angiogenic peptides and their use in gene therapy
|
EP1342477A1
(de)
*
|
1996-07-16 |
2003-09-10 |
Archibald James Mixson, M.D. |
Kationisches Vehikel: DNS Komplexe und ihre Verwendung in Gentherapie
|
US5837283A
(en)
|
1997-03-12 |
1998-11-17 |
The Regents Of The University Of California |
Cationic lipid compositions targeting angiogenic endothelial cells
|
US7112338B2
(en)
|
1997-03-12 |
2006-09-26 |
The Regents Of The University Of California |
Cationic liposome delivery of taxanes to angiogenic blood vessels
|
US6126965A
(en)
*
|
1997-03-21 |
2000-10-03 |
Georgetown University School Of Medicine |
Liposomes containing oligonucleotides
|
US7262173B2
(en)
|
1997-03-21 |
2007-08-28 |
Georgetown University |
Chemosensitizing with liposomes containing oligonucleotides
|
EP1012331B1
(de)
*
|
1997-07-01 |
2006-03-29 |
Isis Pharmaceuticals, Inc. |
Zusammensetzungen und verfahren zur verabreichung von oligonukleotiden über die speiseröhre
|
WO1999015643A2
(en)
*
|
1997-09-25 |
1999-04-01 |
University Of Florida |
ANTISENSE OLIGONUCLEOTIDE COMPOSITIONS TARGETED TO ANGIOTENSI N CONVERTING ENZYME mRNA AND METHODS OF USE
|
US6734171B1
(en)
*
|
1997-10-10 |
2004-05-11 |
Inex Pharmaceuticals Corp. |
Methods for encapsulating nucleic acids in lipid bilayers
|
US6221425B1
(en)
|
1998-01-30 |
2001-04-24 |
Advanced Cardiovascular Systems, Inc. |
Lubricious hydrophilic coating for an intracorporeal medical device
|
US6472375B1
(en)
|
1998-04-16 |
2002-10-29 |
John Wayne Cancer Institute |
DNA vaccine and methods for its use
|
US6432925B1
(en)
|
1998-04-16 |
2002-08-13 |
John Wayne Cancer Institute |
RNA cancer vaccine and methods for its use
|
US6129757A
(en)
*
|
1998-05-18 |
2000-10-10 |
Scimed Life Systems |
Implantable members for receiving therapeutically useful compositions
|
WO1999060012A1
(en)
*
|
1998-05-21 |
1999-11-25 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for non-parenteral delivery of oligonucleotides
|
US7241617B2
(en)
*
|
1998-07-03 |
2007-07-10 |
Dnavec Research, Inc. |
Sendai viral vectors comprising foreign genes inserted between the R1 and R2 Loci
|
US6135976A
(en)
|
1998-09-25 |
2000-10-24 |
Ekos Corporation |
Method, device and kit for performing gene therapy
|
US6958147B1
(en)
|
1998-10-26 |
2005-10-25 |
Licentia Ltd |
Use of VEGF-C to prevent restenosis
|
AU764660B2
(en)
|
1999-01-08 |
2003-08-28 |
Lonza Cologne Ag |
Use of the cell's own transport system for transferring nucleic acids across the nuclear membrane
|
WO2000058511A1
(en)
|
1999-03-26 |
2000-10-05 |
Ludwig Institute For Cancer Research |
Screening and therapy for lymphatic disorders involving the flt4 receptor tyrosine kinase (vegfr-3)
|
US6764820B2
(en)
*
|
1999-03-26 |
2004-07-20 |
Ludwig Institute For Cancer Research |
Screening for lymphatic disorders involving the FLT4 receptor tyrosine kinase (VEGFR-3)
|
AU4206200A
(en)
|
1999-04-05 |
2000-10-23 |
Adherex Technologies Inc. |
Compounds and methods for stimulating beta-catenin mediated gene expression and differentiation
|
US6352996B1
(en)
|
1999-08-03 |
2002-03-05 |
The Stehlin Foundation For Cancer Research |
Liposomal prodrugs comprising derivatives of camptothecin and methods of treating cancer using these prodrugs
|
US6586411B1
(en)
*
|
2000-08-16 |
2003-07-01 |
Mayo Foundation For Medical Education And Research |
System for monitoring the location of transgenes
|
CA2381941A1
(en)
*
|
1999-08-17 |
2001-02-22 |
Mayo Foundation For Medical Education And Research |
System for monitoring the expression and/or location of transgenes
|
US6632800B1
(en)
|
1999-08-17 |
2003-10-14 |
Mayo Foundation For Medical Education And Research |
System for monitoring the expression of transgenes
|
WO2001017511A1
(fr)
*
|
1999-09-03 |
2001-03-15 |
Chugai Seiyaku Kabushiki Kaisha |
Procede de liberation intracellulaire prolongee de medicaments et de preparations
|
PT1142590E
(pt)
*
|
1999-10-29 |
2008-10-27 |
Anges Mg Inc |
Terapêutica génica para doença isquémica diabética
|
WO2001043778A1
(en)
*
|
1999-12-17 |
2001-06-21 |
Gene Therapy Systems, Inc. |
Use of cationic lipids for intracellular protein delivery
|
US20030170210A1
(en)
*
|
2000-01-19 |
2003-09-11 |
Ichiro Masaki |
Use of paramyxovirus vector in gene transfer into blood vessel
|
US6965010B2
(en)
*
|
2000-02-25 |
2005-11-15 |
Licentia, Ltd. |
Materials and methods involving hybrid vascular endothelial growth factor DNAs and proteins
|
WO2002007776A1
(en)
*
|
2000-07-26 |
2002-01-31 |
University Of Maryland Baltimore |
The protein kinase domain of the large subunit of herpes simplex type 2 ribonucleotide reductase (icp10pk) has anti-apoptopic activity
|
JP2002142770A
(ja)
*
|
2000-11-08 |
2002-05-21 |
Dnavec Research Inc |
循環系への遺伝子送達用パラミクソウイルスベクター
|
EP1361896A2
(de)
*
|
2001-01-23 |
2003-11-19 |
Boston Scientific Corporation |
Methode zur lokalen myocardialen injektion zur behandlung ischämischen myocardiums
|
US6509027B2
(en)
|
2001-02-12 |
2003-01-21 |
Supergen, Inc. |
Injectable pharmaceutical composition comprising coated particles of camptothecin
|
US6497896B2
(en)
|
2001-02-12 |
2002-12-24 |
Supergen, Inc. |
Method for administering camptothecins via injection of a pharmaceutical composition comprising microdroplets containing a camptothecin
|
US20040253272A1
(en)
*
|
2001-08-02 |
2004-12-16 |
Yasufumi Kaneda |
Process for producing inactivated virus envelopes
|
US20040249130A1
(en)
*
|
2002-06-18 |
2004-12-09 |
Martin Stanton |
Aptamer-toxin molecules and methods for using same
|
US20040022727A1
(en)
*
|
2002-06-18 |
2004-02-05 |
Martin Stanton |
Aptamer-toxin molecules and methods for using same
|
JPWO2004035779A1
(ja)
*
|
2002-08-27 |
2006-02-16 |
アンジェスMg株式会社 |
ウイルスエンベロープを用いた生体分子の導入方法ならびにそのための組成物およびシステム
|
US20060099597A1
(en)
*
|
2002-11-21 |
2006-05-11 |
Yasufumi Kaneda |
Method of isolating nucleic acid having desired functional property and kit therefor
|
US8853376B2
(en)
|
2002-11-21 |
2014-10-07 |
Archemix Llc |
Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
|
US20040204435A1
(en)
*
|
2003-04-09 |
2004-10-14 |
Joachim Liehr |
Alternating treatment with topoisomerase I and topoisomerase II inhibitors
|
AU2003252493A1
(en)
*
|
2003-07-09 |
2005-01-28 |
Anges Mg, Inc. |
Pharmaceutical composition containing decoy and method of using the same
|
ES2357772T3
(es)
*
|
2004-06-14 |
2011-04-29 |
Ishihara Sangyo Kaisha, Ltd. |
Composición liofilizada de envuelta viral inactivada con actividad de fusión de membrana.
|
EP2110667A1
(de)
|
2005-01-20 |
2009-10-21 |
University Of Rochester |
Mit Thioredoxin interagierendes Protein (TXNIP) als Regulator der Gefäßfunktion
|
EP1919944B1
(de)
|
2005-08-15 |
2011-03-23 |
Vegenics Pty Ltd |
Modifizierte vegf und pdgf mit verbesserten angiogenen eigenschaften
|
US7875602B2
(en)
*
|
2005-10-21 |
2011-01-25 |
Sutter West Bay Hospitals |
Camptothecin derivatives as chemoradiosensitizing agents
|
EP1969003B8
(de)
|
2005-12-14 |
2010-11-10 |
Hermo Pharma Ltd. |
Verwendungen eines neurotrophischen Faktors
|
FI20070808A0
(fi)
|
2007-10-25 |
2007-10-25 |
Mart Saarma |
GDNF:n silmukointivariantit ja niiden käytöt
|
FI20080326A0
(fi)
|
2008-04-30 |
2008-04-30 |
Licentia Oy |
Neurotroofinen tekijä MANF ja sen käytöt
|
EP2345415B1
(de)
|
2008-09-16 |
2015-01-21 |
GenomIdea Inc. |
Therapeutisches/prophylaktisches mittel gegen prostatakrebs
|
WO2010040023A2
(en)
|
2008-10-03 |
2010-04-08 |
Government Of The United States Of America, As Represented By The Secretary, Department Of Health & Human Services |
Methods and compositions for protein delivery
|
EP2440234A4
(de)
|
2009-06-10 |
2013-11-06 |
Univ New York |
Immunologische anzielung pathologischer tau-proteine
|
EP3252068A3
(de)
|
2009-10-12 |
2018-03-14 |
Larry J. Smith |
Verfahren und zusammensetzungen zur modulation der genexpression unter verwendung in-vivo- oder in-vitro-verabreichten arzneistoffen auf oligonukleotidbasis
|
US9951117B2
(en)
|
2010-09-02 |
2018-04-24 |
Mayo Foundation For Medical Education And Research |
Vesicular stomatitis viruses
|
CA2847413C
(en)
|
2010-09-02 |
2018-05-22 |
Mayo Foundation For Medical Education And Research |
Vesicular stomatitis viruses
|
WO2012092341A1
(en)
|
2010-12-28 |
2012-07-05 |
University Of Rochester |
Methods of modifying insulin signaling using biliverdin reductase (bvr) and bvr derived peptides
|
ES2586411T3
(es)
|
2011-03-04 |
2016-10-14 |
New York University |
Macrociclos sustitutos de enlace de hidrógeno como moduladores de Ras
|
EP2710037B1
(de)
|
2011-05-19 |
2019-07-31 |
The Regents of The University of Michigan |
Alpha-2-integrin-bindemittel und verwendung zur hemmung der krebszellenproliferation
|
SI2753346T1
(sl)
|
2011-09-07 |
2020-09-30 |
Mount Sinai School Of Medicine |
Ceramidaza in diferenciacija celic
|
HUE049729T2
(hu)
|
2011-11-30 |
2020-10-28 |
Ludwig Inst For Cancer Res Ltd |
INKT cella modulátorok és ezek alkalmazásának módszerei
|
GB201120860D0
(en)
|
2011-12-05 |
2012-01-18 |
Cambridge Entpr Ltd |
Cancer immunotherapy
|
US9255086B2
(en)
|
2012-02-16 |
2016-02-09 |
New York University |
Control of hypoxia-inducible gene expression with oligooxopiperazine nonpeptidic helix mimetics
|
JP2015527296A
(ja)
|
2012-03-26 |
2015-09-17 |
アメリカ合衆国 |
哺乳動物細胞へのパッケージングされたrnaの新規の送達
|
CA2874146C
(en)
|
2012-06-01 |
2023-03-21 |
Icahn School Of Medicine At Mount Sinai |
Ceramide levels in the treatment and prevention of infections
|
US9321749B1
(en)
|
2012-07-25 |
2016-04-26 |
Globavir Biosciences, Inc. |
Heterocyclic compounds and uses thereof
|
US9499817B2
(en)
|
2012-09-06 |
2016-11-22 |
The University Of Chicago |
Antisense polynucleotides to induce exon skipping and methods of treating dystrophies
|
WO2014063155A1
(en)
|
2012-10-21 |
2014-04-24 |
University Of Rochester |
Thy1 (cd90) as a novel therapy to control adipose tissue accumulation
|
US20140287932A1
(en)
|
2012-10-25 |
2014-09-25 |
Whitehead Institute For Biomedical Research |
Super-enhancers and methods of use thereof
|
EP2956159A1
(de)
|
2013-02-14 |
2015-12-23 |
UCL Business Plc. |
Mittel zur induzierung von lymphangiogenese zur verwendung bei der behandlung von zystennierenerkrankungen
|
HUE048687T2
(hu)
|
2013-02-18 |
2020-08-28 |
Vegenics Pty Ltd |
Ligandum kötõ molekulák és alkalmazásaik
|
CA2905449A1
(en)
|
2013-03-14 |
2014-10-02 |
Icahn School Of Medicine At Mount Sinai |
Therapeutic acid ceramidase compositions and methods of making and using them
|
WO2014191630A2
(en)
|
2013-05-28 |
2014-12-04 |
Helsingin Yliopisto |
Non-human animal model encoding a non-functional manf gene
|
ES2864667T3
(es)
|
2013-08-16 |
2021-10-14 |
Univ Rochester |
Péptidos diseñados para la modulación de la barrera de unión estrecha
|
KR102467982B1
(ko)
|
2013-12-16 |
2022-11-16 |
더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 |
Vlp-레플리콘을 이용한 클래스 ii mhc 항원의 전달에 의한 암 면역요법
|
HUE052604T2
(hu)
|
2015-04-08 |
2021-05-28 |
Univ Chicago |
Készítmények és eljárások 2C típusú végtag-öv izomdisztrófia javítására exon-átugrás alkalmazásával
|
DK3288379T3
(da)
|
2015-05-01 |
2022-02-07 |
Univ Michigan Regents |
Peptidsammensætninger og anvendelsesmåder
|
EP3371211A4
(de)
|
2015-11-04 |
2019-08-21 |
Icahn School of Medicine at Mount Sinai |
Verfahren zur behandlung von tumoren und krebs sowie identifizierung von kandidatenpatienten für solch eine behandlung
|
WO2017189730A1
(en)
|
2016-04-26 |
2017-11-02 |
Icahn School Of Medicine At Mount Sinai |
Treatment of hippo pathway mutant tumors and methods of identifying subjects as candidates for treatment
|
EP3536329B1
(de)
|
2016-11-01 |
2022-08-31 |
Osaka University |
Antikrebsmittel mit hvj-e und neutralisierenden antikörpers gegen pd-1
|
CN110072537B
(zh)
|
2016-12-06 |
2023-03-14 |
国立大学法人大阪大学 |
朊病毒样蛋白病用治疗药
|
CA3090354A1
(en)
|
2018-03-27 |
2019-10-03 |
Enzyvant Therapeutics Gmbh |
Farber disease markers and uses thereof
|
CN112654366A
(zh)
|
2018-06-21 |
2021-04-13 |
罗切斯特大学 |
治疗或抑制亨廷顿病发作的方法
|
US20220088158A1
(en)
|
2019-01-23 |
2022-03-24 |
Aceragen, Inc. |
Method of ameliorating a pro-inflammatory immunophenotype in farber disease subjects by repeated administration of a recombinant human acid ceramidase
|
EP3923962A2
(de)
|
2019-02-13 |
2021-12-22 |
University of Rochester |
Gennetzwerke, die die remyelinisierung des menschlichen gehirns vermitteln
|
US20220249364A1
(en)
|
2019-06-05 |
2022-08-11 |
University Of Rochester |
Designed Inhibitors of Tight Junction Formation
|
US20230372397A1
(en)
|
2020-10-06 |
2023-11-23 |
Iovance Biotherapeutics, Inc. |
Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
|
WO2022076606A1
(en)
|
2020-10-06 |
2022-04-14 |
Iovance Biotherapeutics, Inc. |
Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
|
WO2022133149A1
(en)
|
2020-12-17 |
2022-06-23 |
Iovance Biotherapeutics, Inc. |
Treatment of cancers with tumor infiltrating lymphocytes
|
JP2023554395A
(ja)
|
2020-12-17 |
2023-12-27 |
アイオバンス バイオセラピューティクス,インコーポレイテッド |
Ctla-4及びpd-1阻害剤と併用した腫瘍浸潤リンパ球療法による治療
|
WO2022225981A2
(en)
|
2021-04-19 |
2022-10-27 |
Iovance Biotherapeutics, Inc. |
Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies
|
WO2023009716A1
(en)
|
2021-07-28 |
2023-02-02 |
Iovance Biotherapeutics, Inc. |
Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with kras inhibitors
|
AR127482A1
(es)
|
2021-10-27 |
2024-01-31 |
Iovance Biotherapeutics Inc |
Sistemas y métodos para coordinar la fabricación de células para inmunoterapia específica de paciente
|
US20230270818A1
(en)
|
2021-11-02 |
2023-08-31 |
University Of Rochester |
Tcf7l2 mediated remyelination in the brain
|
WO2023086803A1
(en)
|
2021-11-10 |
2023-05-19 |
Iovance Biotherapeutics, Inc. |
Methods of expansion treatment utilizing cd8 tumor infiltrating lymphocytes
|
WO2023192998A1
(en)
|
2022-04-01 |
2023-10-05 |
Icahn School Of Medicine At Mount Sinai |
Treating orthopedic injury with a vector driving expression of acid ceramidase
|